Stockscreener 앱 받기
1.575
4.27%
-0.065
전일 마감가:
$1.64
열려 있는:
$1.63
하루 거래량:
41,164
Relative Volume:
0.19
시가총액:
$20.55M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-6.82%
1개월 성능:
-4.27%
6개월 성능:
-96.71%
1년 성능:
-93.86%
1일 변동 폭
$1.57
$1.64
1주일 범위
$1.43
$1.72
52주 변동 폭
$1.38
$53.79
Q 32 Bio Inc Stock (QTTB) Company Profile
명칭
Q 32 Bio Inc
전화
781-999-0232
주소
830 WINTER STREET, WALTHAM
QTTB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
1.575 | 20.55M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.78 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.31 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.38 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.80 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.47 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-02-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-12-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-12-11 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-12-11 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2024-12-11 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-10-24 | 개시 | Raymond James | Strong Buy |
| 2024-09-11 | 개시 | Wells Fargo | Overweight |
| 2024-06-17 | 개시 | Guggenheim | Buy |
| 2024-05-21 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Oppenheimer | Outperform |
| 2024-04-02 | 개시 | Piper Sandler | Overweight |
| 2023-07-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-02-22 | 재확인 | BTIG Research | Neutral |
| 2022-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-02-22 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-03-02 | 개시 | Stifel | Hold |
| 2020-12-14 | 재개 | H.C. Wainwright | Buy |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-02-24 | 개시 | Chardan Capital Markets | Buy |
| 2019-11-01 | 개시 | Oppenheimer | Perform |
| 2019-09-10 | 개시 | Robert W. Baird | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
모두보기
Q 32 Bio Inc 주식(QTTB)의 최신 뉴스
Q32 Bio Stock Turns Retail Trader Heads After FDA Grants Fast Track For Alopecia Drug - MSN
Layoff Tracker: BMS Closes Manufacturing Plant, Arvinas Axes One-Third of Staff - BioSpace
Analysts Provide Insight Into Q32 Bio Inc’s (QTTB) Potential. - Stocksregister
Closing Figures: Q32 Bio Inc (QTTB)’s Positive Finish at 1.60, Up 2.89 - DWinneX
Q32 Bio Stock Turns Retail Trader Heads After FDA Grants Fast Track For Alopecia Drug By Stocktwits - Investing.com India
Fierce Biotech Layoff Tracker 2025: Pliant cuts 45% of workforce; Arvinas lays off a third of staffers - Fierce Biotech
Q32 Bio Inc (NASDAQ: QTTB) Prices Could Soar To Much Higher Levels In Coming Months - Marketing Sentinel
Evaluating QTTB’s financial ratios for a profitable investment - uspostnews.com
Q32 Bio Announces FDA Fast Track Designation Granted To Bempikibart (ADX-914) For The Treatment Of Alopecia Areata - marketscreener.com
Q32 Bio Inc. Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata - marketscreener.com
Scotiabank Has Lowered Expectations for goeasy (TSE:GSY) Stock Price - American Banking and Market News
Analysts Set Q32 Bio Inc. (NASDAQ:QTTB) PT at $24.71 - Defense World
Q32 Bio announces board member resignation By Investing.com - Investing.com Nigeria
Q32 Bio IncMark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025 - marketscreener.com
Q32 Bio Board Member Mark Iwicki Resigns - TipRanks
Q32 Bio announces board member resignation - Investing.com
Can Sezzle Inc (NASDAQ: SEZL) Still Be Considered A Loss When It’s Up 5.08% YTD? - Marketing Sentinel
Q32 Bio doses first patient in both parts of SIGNAL-AA trial - TipRanks
Q32 Bio Doses First Patients In Both Part A Open-Label Extension And Part B Of Signal-Aa Phase 2A Trial - marketscreener.com
Breakthrough: Q32 Bio's Alopecia Treatment Maintains Effects 7 Months After Last Dose - Stock Titan
Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata - PR Newswire
Raymond James Financial Inc. Buys New Stake in Q32 Bio Inc. (NASDAQ:QTTB) - Defense World
Q32 Bio Files For Mixed Shelf Of Up To $200 MillionSEC Filing - MarketScreener
Wayfair Inc (NYSE: W) Has Dropped -40.68% Year-To-Date (YTD): Any Trouble Coming? - Marketing Sentinel
QTTB stock touches 52-week low at $1.38 amid market challenges By Investing.com - Investing.com South Africa
All You Need to Know About Q32 Bio (QTTB) Rating Upgrade to Buy - MSN
QTTB stock touches 52-week low at $1.38 amid market challenges - Investing.com India
Arbe Robotics Ltd (NASDAQ: ARBE): How To Buy And When To Buy And Its Performance & Trends - Marketing Sentinel
Russell hits bear market with small caps buffeted by tariff wave - The Edge Malaysia
Q32 Bio Inc. (NASDAQ:QTTB) Receives $24.71 Average Target Price from Brokerages - Defense World
Biotech layoff tracker: 21 companies cut 1,000 jobs in Q1 2025 - The Business Journals
QTTB stock touches 52-week low at $1.79 amid market challenges By Investing.com - Investing.com South Africa
QTTB stock touches 52-week low at $1.79 amid market challenges - Investing.com India
Immunosuppressive and Anti-complement Therapies in C3 Glomerulopathy - Medscape
Immunosuppressive Therapies in C3 Glomerulopathy - Medscape
Oppenheimer maintains Q32 Bio at Outperform, $20 target - Investing.com India
Oppenheimer maintains Q32 Bio at Outperform, $20 target By Investing.com - Investing.com UK
Wells Fargo & Company Lowers Q32 Bio (NASDAQ:QTTB) Price Target to $15.00 - Defense World
Q32 Bio price target lowered to $15 from $16 at Wells Fargo - TipRanks
Could Aehr Test Systems (AEHR)’s Current Volatility Hinder Its Future Potential? - Marketing Sentinel
Q32 Bio Inc’s Intellectual Property Challenges: Navigating Risks and Competitive Pressures - TipRanks
Q32 Bio Reports Promising Trial Results and Financials - TipRanks
Q32 Bio: Q4 Earnings Snapshot - Midland Daily News
Q32 Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Q 32 Bio Inc (QTTB) 재무 분석
Q 32 Bio Inc (QTTB)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Q 32 Bio Inc 주식 (QTTB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Violette Shelia M. | Chief Scientific Officer |
Oct 11 '24 |
Option Exercise |
3.12 |
4,574 |
14,271 |
17,874 |
| Violette Shelia M. | Chief Scientific Officer |
Oct 08 '24 |
Option Exercise |
3.12 |
13,300 |
41,496 |
13,300 |
0.52%
0.52%
자본화:
|
볼륨(24시간):